Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79959.100.1484%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Enveric Biosciences Inc

ENVBNASDAQ
Trade with Public
Trade with Public
$1.39
-0.05-3.47%
At close: Sep 4, 5:00 PM EST
$1.44
0.04993.59%
After Hours: Sep 4, 9:12 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

Enveric Biosciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Enveric Biosciences (ENVB).

Price Target Range — 2 Quarters

Analyst Consensus — 1 Analysts

1Buy
Consensus RatingBuy# Analysts1Avg. Consensus PT$10Upside to Avg. PT+594.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Mar 6, 2025HC Wainwright & Co.Vernon BernardinoMaintainedBuy$10
Jan 30, 2024HC Wainwright & Co.Vernon BernardinoInitiateBuy$10

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Enveric Biosciences, Maintains $10 Price Target

HC Wainwright & Co. analyst Vernon Bernardino reiterates Enveric Biosciences (NASDAQ:ENVB) with a Buy and maintains $10 price target.
Benzinga Newsdesk

US Stocks Likely To Open Higher Ahead Of Nvidia Earnings: S&P 500's Four-Day Fall Was A 'Non-Event,' Says Expert

U.S. stock futures rose on Wednesday following two consecutive days of mixed close this week. All futures advanced in premarket trading.
Rishabh Mishra

PRO
HC Wainwright & Co. Initiates Coverage On Enveric Biosciences with Buy Rating, Announces Price Target of $10

HC Wainwright & Co. analyst Vernon Bernardino initiates coverage on Enveric Biosciences (NASDAQ:ENVB) with a Buy rating and announces Price Target of $10.
Benzinga Newsdesk

Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2022

Upgrades
Benzinga Insights

PRO
Alliance Global Partners Initiates Coverage On Enveric Biosciences with Buy Rating, Announces Price Target of $1.25

Alliance Global Partners analyst James Molloy initiates coverage on Enveric Biosciences (NASDAQ:ENVB) with a Buy rating and announces Price Target of $1.25.
Benzinga Newsdesk

Are Psychedelics Stocks In Trouble Or Is The Market Reaching Maturity?

Long gone is the heyday of investor enthusiasm and easy access to capital that marked the launch of the psychedelics industry into the public markets. In recent months, psychedelics stocks entered into a period of turmoil characterized by declining valuations and a generalized capital dry spell.
Natan Ponieman

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved